[144] Rocket Pharmaceuticals, Inc. SEC Filing
Rhea-AI Filing Summary
Form 144 filing for Rocket Pharmaceuticals, Inc. (RCKT) shows a proposed sale of 1,004 common shares through Fidelity Brokerage Services with an aggregate market value of $3,077.46, planned for 08/18/2025 on NASDAQ. The shares were acquired by the filer on 08/14/2025 through restricted stock vesting as compensation. The filing also discloses two recent sales by the same person in the prior three months: 587 shares sold on 05/20/2025 for $3,783.80 and 12,109 shares sold on 08/14/2025 for $36,553.44. The notice includes the signer’s representation that they are not aware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale notification; small-dollar proposed sale following restricted stock vesting and prior recent dispositions.
The filing documents a prospectus-exempt sale under Rule 144 of 1,004 common shares valued at $3,077.46 and states the shares were obtained via restricted stock vesting on 08/14/2025 as compensation. The filer previously sold 587 and 12,109 shares in the past three months, generating gross proceeds of $3,783.80 and $36,553.44 respectively. From a compliance viewpoint, the form provides required broker and acquisition details and the signer’s attestation about material nonpublic information.
TL;DR: Filing is a standard disclosure of insider sales and compensation-related share vesting; procedural compliance appears met.
The document identifies the broker, sale timing, acquisition method (restricted stock vesting), and includes the mandatory representation regarding undisclosed material information. It also lists recent sales by the same person during the three-month lookback. The disclosure content aligns with Rule 144 reporting requirements and provides transparency about insider stock movements.